Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

65.75 +0.48 (+0.74%)
Streaming Delayed Price Updated: 12:32 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Michael Elliott Named to 2022 Empower Advocate Executive Role Model List.
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
From Gilead Sciences, Inc.
Via Business Wire
4 Questions With Betty Chiang: Addressing Health Disparities in the Asian Community
SOURCE: Gilead Sciences 
Via 3BL Media
Portugal's Positive Approach to Teaching Teens about the Birds, Bees and STIs
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead at Forefront of Herculean Effort to Combat COVID-19
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
From Gilead Sciences, Inc.
Via Business Wire
Living with Metastatic Bladder Cancer: Joey's Journey
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Product Recall
Exposures Legal Product Safety
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
From Gilead Sciences, Inc.
Via Business Wire
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
From Gilead Sciences, Inc.
Via Business Wire
Playwright Lee Raines Shines a Spotlight on the Criminalization of HIV
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies
SOURCE: Gilead Sciences 
Via 3BL Media
Closing the Representation Gap in Schools, One Black Male Teacher at a Time
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Product Recall
Exposures Legal Product Safety
Opinion: The Road to Ending Visceral Leishmaniasis
SOURCE: Gilead Sciences 
Via 3BL Media
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027 Bio-based Platform Chemicals Market Overview The Bio-based Platform Chemicals Market size is forecast to reach... 
Via iCrowdNewswire
Topics Derivatives
Exposures COVID-19 Derivatives
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
On Earth Day, Gilead Marks Strides in Environmental Sustainability
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Emissions
Gilead Sciences Announces First Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program
SOURCE: Gilead Sciences 
Via 3BL Media
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Mom Celebrates Sons' Milestones: Julie's CAR T-cell Therapy Journey
SOURCE: Gilead Sciences 
Via 3BL Media
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
From Gilead Sciences, Inc.
Via Business Wire
The Translatinx Network Helps a Resilient Community 'Live Its Truth'
SOURCE: Gilead Sciences 
Via 3BL Media
Tour for Diversity in Medicine, Gilead Sciences and the Advisory Group to SHC Vaccine Equity Program to Receive Booker T. Washington Award From National Minority Quality Forum
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
From Gilead Sciences, Inc.
Via Business Wire
Four Questions With Anu Osinusi: Gilead's Commitment to People Living With Viral Hepatitis
SOURCE: Gilead Sciences 
Via 3BL Media
FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies
From Gilead Sciences, Inc.
Via Business Wire
Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.